Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

Recruiting now · Phase 1

Conditions studied: Small Cell Lung Cancer

In brief

This is an open-label study of NMS-03305293 with Temozolomide (TMZ) in patients with Small Cell Lung Cancer (SCLC). The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with TMZ.

Key facts

Study ID

NCT06931626

Run by

Nerviano Medical Sciences

People needed

10

Starts

2025-08-15

Expected to finish

2027-02-28

Last updated by the study team

2026-07-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• OSF Saint Francis Medical Center — Peoria, Illinois, United States (enrolling)
• Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
• Tennessee Oncology, PLLC — Nashville, Tennessee, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.